• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Science 37 Holdings Inc. (Amendment)

    2/14/22 4:34:58 PM ET
    $SNCE
    Computer Software: Prepackaged Software
    Technology
    Get the next $SNCE alert in real time by email
    SC 13G/A 1 d318637dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Science 37 Holdings, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    808644108

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    Evan K. Hall, Esq.

    Haynes and Boone, LLP

    2323 Victory Avenue, Suite 700

    Dallas, Texas 75219-7673

    (214) 651-5000

     

     

     


    SCHEDULE 13G

     

    CUSIP No. 808644108      

     

      1    

      Names of Reporting Persons

     

      Ikarian Capital, LLC

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      0 (1)

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      0 (1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0 (1)

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      0.0% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      IA

     

    (1)

    Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information.


    SCHEDULE 13G

     

    CUSIP No. 808644108      

     

      1    

      Names of Reporting Persons

     

      Chart Westcott

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      0 (1)

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      0 (1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0 (1)

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      0.0% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      IN; HC

     

    (1)

    Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information.


    SCHEDULE 13G

     

    CUSIP No. 808644108      

     

      1    

      Names of Reporting Persons

     

      Neil Shahrestani

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      0 (1)

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      0 (1)

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0 (1)

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      0.0% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      IN; HC

     

    (1)

    Represents shares held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership, and certain separately managed accounts. See Item 2 for more information.


    Item 1.

     

      (a)

    Name of Issuer:

    Science 37 Holdings, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    600 Corporate Pointe, Suite 320, Culver City, CA 90230

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company (“Ikarian Capital”), Chart Westcott and Neil Shahrestani (collectively referred herein as the “Reporting Persons”). Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), and certain separately managed accounts managed by Ikarian Capital (collectively, the “Managed Accounts”) are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Westcott, and Mr. Shahrestani. Accordingly, each of Mr. Westcott and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The Managed Accounts disclaim beneficial ownership of the shares held by the Fund.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.

     

    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.


    (d)

    Title and Class of Securities:

    Common Stock, par value $0.0001 per share.

     

    (e)

    CUSIP No.:

    808644108    

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☒    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☒    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.

    Ownership

    The information set forth in Item 2(a) is incorporated by reference herein.

     

    (a)

    Amount Beneficially Owned as of December 31, 2021: See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of Class as of December 31, 2021: See Item 11 on the cover page(s) hereto.

     

    (c)

    As of December 31, 2021, number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    The information set forth in Item 2(a) is incorporated by reference herein.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2022

     

    IKARIAN CAPITAL, LLC
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    CHART WESTCOTT

    /s/ Chart Westcott

    NEIL SHAHRESTANI

    /s/ Neil Shahrestani


    EXHIBIT INDEX

     

    Exhibit

      

    Description of Exhibit

    99.1    Joint Filing Agreement (filed herewith).
    Get the next $SNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNCE

    DatePrice TargetRatingAnalyst
    11/1/2021$15.00Buy
    Lake Street
    11/1/2021$15.00Outperform
    Robert W. Baird
    11/1/2021Outperform
    William Blair
    11/1/2021$15.00Outperform
    Baird
    10/22/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $SNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

      MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company's role in a registrational Phase 3 asthma study, which Science 37 contributed 28% of the total patient enrollment. The FDA evaluated internal processes, technology, data integrity, patien

      4/8/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

      MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

      1/14/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

      MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial

      11/21/24 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      3/14/24 4:17:56 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      3/13/24 5:15:52 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Science 37 Holdings Inc. (Amendment)

      SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)

      1/31/24 5:15:22 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Thermo Fisher Scientific Inc.

      4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:26:37 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Thermo Fisher Scientific Inc.

      4 - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:25:33 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • New insider Thermo Fisher Scientific Inc. claimed ownership of 17,379,797 shares (SEC Form 3) (Amendment)

      3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)

      3/14/24 4:20:09 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

      MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing

      1/14/25 8:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

      RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera

      4/25/23 7:59:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Adds New Head of Quality, Irena Lambridis

      RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA

      4/18/23 7:59:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Financials

    Live finance-specific insights

    See more
    • Science 37 Reports Third Quarter 2023 Financial Results

      RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%

      11/7/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

      RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i

      10/24/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Science 37 Reports Second Quarter 2023 Financial Results

      RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial

      8/8/23 6:00:00 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Science 37 Holdings Inc.

      15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/22/24 6:50:27 PM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Science 37 Holdings Inc.

      EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/15/24 12:15:04 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Science 37 Holdings Inc.

      EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)

      3/15/24 12:15:11 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology

    $SNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Science 37 with a new price target

      Lake Street initiated coverage of Science 37 with a rating of Buy and set a new price target of $15.00

      11/1/21 9:12:40 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • Robert W. Baird initiated coverage on Science 37 with a new price target

      Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00

      11/1/21 7:43:34 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology
    • William Blair initiated coverage on Science 37 Hldgs

      William Blair initiated coverage of Science 37 Hldgs with a rating of Outperform

      11/1/21 5:42:17 AM ET
      $SNCE
      Computer Software: Prepackaged Software
      Technology